Washington Defunded Harm Reduction. The Newsroom Covering It Couldn't Outlast the Cut.

Filter Treated What You Know About Your Own Life as Expertise

In September 2020, deep into pandemic lockdown, a writer named Sessi Kuwabara Blanchard sat down and described her nightly ritual: cracking open a seltzer flavored with her drug of choice, GHB, while her roommates reached for weed or beer instead. She wrote about the night her therapist heard the word GHB and reflexively called it “the date-rape drug” — and about how she went quiet in that room after that, because the label had nothing to do with her actual life. She wasn’t confessing. She was reporting, on how a stigma phrase erases the people who don’t fit it, using her own use as the primary source. Filter ran it, because that was the entire premise of the outlet Will Godfrey had built since 2018: that a person’s direct account of using drugs is data, not a cry for help.

The government spent this year deciding that giving you a way to check what’s actually in your dope sends the wrong message. The newsroom built to prove that message wrong ran out of money first.

On August 11, 2026, Godfrey — Filter’s editor-in-chief — posted a page titled “A Statement About Filter,” and it said the thing outlets almost never say plainly: the nonprofit harm-reduction newsroom was “unable to survive an increasingly difficult funding landscape, like too many other harm reduction and independent media organizations in these times,” and it was “shutting down this week.” Eight years of daily coverage — deputy editor Kastalia Medrano, who’d run the newsroom day to day since 2020; senior editor Helen Redmond; tobacco harm reduction fellow Kiran Sidhu; and, across the years, Sessi Kuwabara Blanchard, Alex Norcia, Alexander Lekhtman and dozens of contributors who wrote from inside the thing they were covering — folded into an archive that the board arranged to keep online “for some years… as a community resource,” because even in shutting down, nobody wanted the record erased.

Board member Morgan Godvin, who found Filter a year out of prison, put it the way you’d expect someone to put it if the outlet had actually worked as designed: “Filter treated the experiences that had so often been used to diminish people like me as expertise — it turned isolation into community and lived experience into public knowledge.” Board member Diane Goldstein, a former police lieutenant turned drug policy reformer, said she’d helped build it “because I believe people who use drugs deserve to be seen with dignity, not judged from a distance,” and that watching it close “feels like losing a piece of my own family.” If you’ve ever sat across from a provider, a judge, a parent, or a therapist and watched them flinch at the plain fact of what you use — the way Blanchard’s therapist flinched — you already know what both of them are describing. Filter’s whole editorial bet was that your account of your own life outranks their flinch. That bet doesn’t have a funding model right now.

A “Dear Colleague” Letter Decided Which Supplies Keep You Alive and Which Ones “Send a Message”

Filter didn’t close in a vacuum. It closed four months after the federal government finished making the argument, in writing, that the kind of knowledge Filter published — knowledge that comes from people who use drugs, about what keeps them alive while using — doesn’t deserve public money either.

On April 24, 2026, the Substance Abuse and Mental Health Services Administration sent grantees a Dear Colleague letter — the kind of guidance memo an agency sends to tell states and nonprofits how it will interpret its own funding rules, not a law passed by Congress, but treated by every grantee as one, because defying it risks the whole grant. Signed by Principal Deputy Assistant Secretary Christopher Carroll, it spells out what “harm reduction” — the practice of keeping people who use drugs alive and safer without requiring they stop first — can and can’t be paid for with SAMHSA money going forward, and it does so in service of President Trump’s executive order “Ending Crime and Disorder on America’s Streets.” Naloxone and nalmefene, the medications that reverse an overdose, are still fundable. So are medication lock boxes, sharps disposal, wound care supplies, FDA-approved home HIV and hepatitis test kits, PrEP and PEP navigation, and condoms. What’s not: syringes or needles used to inject drugs, pipes or other safer-smoking supplies, and fentanyl test strips — along with any other drug-checking strip, including ones for xylazine and medetomidine, the sedatives now routinely showing up cut into street fentanyl. No federal dollars, the letter says, for the strip of paper that tells you what’s actually in the bag before you use it.

No federal dollars, the letter says, for the strip of paper that tells you what’s actually in the bag before you use it.

STAT News, which broke the story down for a clinical and policy audience, called it a “clear shift away from harm reduction” and noted it lands on an agency that’s already lost roughly $2 billion in funding and more than half its staff over fifteen months — the National Association of Counties put the county-level fallout in plainer terms: local health departments that lean on SAMHSA block grants now have to rebuild how they fund syringe programs from scratch, mid-year, with no bridge money offered. Fifteen days later, Senator Ed Markey and twenty House and Senate colleagues sent Carroll a letter back, and it’s worth sitting with their numbers: an average of 192 Americans are still dying of overdose every single day even as the national count has fallen to its lowest point in six years — a decline the letter credits substantially to the exact tools the new guidance defunds. Test strips, the letter notes, aren’t illegal anywhere in federal law and are legal to possess in most states; a multi-state observational study by Gelberg et al. in the International Journal of Drug Policy and a separate cohort study in JAMA Network Open both associate strip use with people changing their behavior to use more cautiously — real, tracked signal, though both are observational studies of people who already sought out strips, not randomized proof the strips alone cause the safer behavior. Congress itself, the letter points out, passed the SUPPORT Act reauthorization in December 2025 — unanimously in the Senate — explicitly authorizing states to buy fentanyl and xylazine test strips with opioid response grants. SAMHSA’s new letter tells the same grantees not to.

We’ve Watched Washington Do This Math Before

Harm reduction has survived this fight once already. In 1988, at the peak of the AIDS epidemic, Congress — pushed by Senator Jesse Helms — banned federal AIDS-prevention dollars from syringe exchange, the practice of swapping used needles for clean ones so HIV and hepatitis stop passing hand to hand. The ban held for roughly two decades even as the government’s own science turned against it: a 1995 Institute of Medicine panel found exchanges cut HIV transmission without raising drug use, and by 1997 HHS Secretary Donna Shalala said the evidence met the bar to lift it — and the Clinton administration left the ban standing anyway. It lifted briefly in 2009, then came back within two years. The lesson isn’t that the ban eventually fell. It’s that “the science works” never held the ban up alone; it took two decades of preventable infections before the argument mattered to the people who could change it.

The Cuts Rhyme Because They Come From the Same Idea

Here’s the thesis, stated flat:

The same season the government decided giving people who use drugs a way to check what’s in their dope “facilitates illicit drug use,” the newsroom built to treat those same people as sources of expertise ran out of money to keep saying otherwise — and that’s not two unrelated funding crises. It’s one idea, executed on two different budgets.

The SAMHSA letter and the Filter closure share a premise neither one states directly: that harm reduction’s legitimacy is negotiable, contingent, revocable on a change of administration or a bad grant cycle — never a floor. You can see the same premise in what independent drug-policy journalism has been losing alongside Filter; Faces & Voices of Recovery’s May 2026 policy roundup tracked the SAMHSA guidance in the same month it was noting funding strain across the recovery-advocacy nonprofit sector generally, the exact “harm reduction and independent media organizations” Godfrey’s statement gestured at without naming. Neither the syringe nor the newsroom failed on the merits. Syringe service programs already exist in only about 13 percent of U.S. counties — Markey’s letter cites the gap directly — and the evidence for what happens when that coverage disappears isn’t hypothetical: in 2015, an HIV outbreak tied to injection drug use in rural Scott County, Indiana infected 235 people, an infection rate that outpaced parts of sub-Saharan Africa, and it only slowed after the state reversed its own ban and stood up needle exchange. A modeling study in Clinical Infectious Diseases found that if sterile syringes had been available from the start, roughly 90 percent of those infections — well over 200 people in one county — could have been prevented. That’s the actual cost of “sends the wrong message”: not an abstraction, a documented outbreak with a body count attached to the delay.

That’s the actual cost of “sends the wrong message”: not an abstraction, a documented outbreak with a body count attached to the delay.

If you run a syringe service program, a facility, or any operation that touches federal harm-reduction dollars, the concrete move this week isn’t a wait-and-see — it’s an audit. Pull your last three grant-funded purchase orders and check them against SAMHSA’s list: naloxone, nalmefene, lock boxes, sharps containers, wound care, HIV/hep test kits, PrEP/PEP navigation, and condoms are still fundable; syringes, pipes, and any fentanyl, xylazine, or medetomidine test strip are not, effective now, not at some future renewal date. Programs that keep buying strips or syringes on federal lines without a non-federal funding stream lined up behind them are the ones that get caught flat when an auditor asks. That’s not a hypothetical either — it’s the exact chilling effect Markey’s letter warns is already happening, as programs preemptively drop supplies rather than risk the grant.

What’s Still Here Tonight

None of this took naloxone off the table. If you’re using tonight, the overdose-reversal medication that actually stops a death in progress is still federally funded, still legal, still something a syringe program or health department near you is still allowed to hand out — that door hasn’t closed, even this week. What’s gone is the strip of paper that would’ve told you what was in the bag before you found out the hard way, and the newsroom that would’ve told you, and everyone else, exactly how that decision got made and who signed it.

Filter’s archive stays up for a few more years. Read what’s there while it’s there — the outlet’s coverage of harm reduction exists because people like Blanchard were willing to put their own drug use on the record as evidence, not confession, on everything from GHB to the fentanyl and adulterants now driving most overdose deaths. The government spent this year arguing that the evidence itself is the problem. Filter spent eight years proving, story by story, that it was the opposite: the only kind of evidence that was ever going to be honest enough to work.